Personal information

Verified email domains

Platelets, Platelet function testing, Antiplatelet drugs, Clinical pharmacology, Neurotrophins

Biography

Dr Lordkipanidzé’s major research interest is to bring platelet function testing and molecular biology to clinical settings with the aim of individualizing antiplatelet treatment to specific patient needs.

Activities

Employment (3)

Université de Montréal Faculté de pharmacie: Montreal, QC, CA

2018-06 to present | Associate professor
Employment
Source: Self-asserted source
Marie Lordkipanidze

Institut De Cardiologie de Montreal: Montreal, QC, CA

2013 to present | Principal Investigator (Research Center)
Employment
Source: Self-asserted source
Marie Lordkipanidze

Université de Montréal - Faculté de pharmacie: Montréal, QC, CA

2013-08 to 2018-05 | Assistant Professor
Employment
Source: Self-asserted source
Marie Lordkipanidze

Education and qualifications (5)

University of Birmingham: Birmingham, Birmingham, GB

2010 to 2013 | Postdoctoral Research Fellow
Education
Source: Self-asserted source
Marie Lordkipanidze

Université de Montréal - Faculté de pharmacie: Montréal, QC, CA

2009 to 2010 | Complementary diploma - Drug Research, Development and Evaluation
Education
Source: Self-asserted source
Marie Lordkipanidze

Université de Montréal - Faculté de pharmacie: Montréal, QC, CA

2006 to 2010 | PhD - Clinical pharmacology
Education
Source: Self-asserted source
Marie Lordkipanidze

Université de Montréal - Faculté de pharmacie: Montréal, QC, CA

2004 to 2006 | MSc - Pharmaceutical sciences
Education
Source: Self-asserted source
Marie Lordkipanidze

Université de Montréal - Faculté de pharmacie: Montréal, QC, CA

2000 to 2004 | BPharm
Education
Source: Self-asserted source
Marie Lordkipanidze

Funding (12)

Brain-Derived Neurotrophic Factor in hemostasis and thrombosis

2022-10-01 to 2027-09-30 | Grant
Canadian Institutes of Health Research (Ottawa, CA)
GRANT_NUMBER:

6085a5fb1c154ed99780aaf60f1dd3c6

Source: Self-asserted source
Marie Lordkipanidze via DimensionsWizard

Investigations into the pathophysiology of heat-related cardiovascular risk

2022-10-01 to 2025-09-30 | Grant
Canadian Institutes of Health Research (Ottawa, CA)
GRANT_NUMBER:

1b59b07d1c16d17cff5172e20760ea65

Source: Self-asserted source
Marie Lordkipanidze via DimensionsWizard

Canada Research Chair - Tier 2

2020-10-01 to 2025-09-30 | Grant
Canadian Institutes of Health Research (Ottawa, CA)
GRANT_NUMBER:

e445dbb16eea4181844d078aeaec86f8

Source: Self-asserted source
Marie Lordkipanidze via DimensionsWizard

Neurotrophins in megakaryocytes and platelets

2018-10-01 to 2022-09-30 | Grant
Canadian Institutes of Health Research (Ottawa, CA)
GRANT_NUMBER:

37be72e459adcadf5d5a8d40ffdb8042

Source: Self-asserted source
Marie Lordkipanidze via DimensionsWizard

Étude des mécanismes régulant la diversité des rôles plaquettaires dans la santé et la maladie

2016-04-01 to 2017-03-31 | Grant
Fonds de Recherche du Québec - Santé (Montreal, CA)
GRANT_NUMBER:

34606

Source: Self-asserted source
Marie Lordkipanidze via DimensionsWizard

Étude des mécanismes régulant la diversité des rôles plaquettaires dans la santé et la maladie

2016-04-01 to 2017-03-31 | Grant
Fonds de Recherche du Québec - Santé (Montreal, CA)
GRANT_NUMBER: 33048
Source: Self-asserted source
Marie Lordkipanidze via DimensionsWizard

Reassessment of Anti-Platelet therapy using InDividualized Strategies -Ticagrelor in Patients with Acute Coronary Syndromes Treated by Coronary Artery Bypass Graft Surgery - A Pharmacodynamic and Clinical Study to Decrease Bleeding Risks and Ischemic Complications - The RAPID-TITRATE CABG study

2015-07-01 to 2018-06-30 | Grant
Canadian Institutes of Health Research (Ottawa, CA)
GRANT_NUMBER:

087bf29a722350142d0f86962f9ffbad

Source: Self-asserted source
Marie Lordkipanidze via DimensionsWizard

Deep phenotyping of platelets for precision medicine in cardiovascular disease

2014-03-18 to present | Grant
Canada Foundation for Innovation (Ottawa, CA)
GRANT_NUMBER:

CFI8071

Source: Self-asserted source
Marie Lordkipanidze via DimensionsWizard

The number of aspirin doses (once versus twice daily) and the timing of aspirin intake (evening versus morning) in primary and secondary prevention of cardiovascular disease. A systematic review of the evidence

2014 to 2015 | Grant
National Institute for Health Research (Birmingham, GB)
Source: Self-asserted source
Marie Lordkipanidze

Vascular Network

2013-10-01 to 2018-09-30 | Grant
Canadian Institutes of Health Research (Ottawa, CA)
GRANT_NUMBER:

0e148d8f24aefca1c94df520385cf1d0

Source: Self-asserted source
Marie Lordkipanidze via DimensionsWizard

Do patients who exhibit serious bleeds on anti-platelet therapy have a previously undiagnosed defect in platelet function?

2011 to 2013 | Grant
British Heart Foundation (Birmingham, GB)
Source: Self-asserted source
Marie Lordkipanidze

A systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease

2010 to 2013 | Grant
National Institute for Health Research (Birmingham, GB)
GRANT_NUMBER: 10/36/02
Source: Self-asserted source
Marie Lordkipanidze

Peer review (262 reviews for 17 publications/grants)

Review activity for Arteriosclerosis, thrombosis, and vascular biology. (8)
Review activity for Blood advances. (2)
Review activity for Blood. (1)
Review activity for BMJ (2)
Review activity for Canadian journal of cardiology. (21)
Review activity for Circulation : (2)
Review activity for Circulation research : (1)
Review activity for Circulation. (6)
Review activity for Journal of the American Heart Association. (5)
Review activity for Journal of thrombosis and haemostasis. (74)
Review activity for Platelets (51)
Review activity for Research and practice in thrombosis and haemostasis. (5)
Review activity for Scientific reports. (3)
Review activity for TH open. (11)
Review activity for The Lancet. (2)
Review activity for Thrombosis and haemostasis. (41)
Review activity for Thrombosis research. (27)